150 related articles for article (PubMed ID: 32343488)
1. Tripartite motif 10 regulates cardiac hypertrophy by targeting the PTEN/AKT pathway.
Yang H; Wang XX; Zhou CY; Xiao X; Tian C; Li HH; Yin CL; Wang HX
J Cell Mol Med; 2020 Jun; 24(11):6233-6241. PubMed ID: 32343488
[TBL] [Abstract][Full Text] [Related]
2. Tripartite motif 27 promotes cardiac hypertrophy via PTEN/Akt/mTOR signal pathways.
Chen Y; Liu Z; Hu Z; Feng X; Zuo L
Bioengineered; 2022 Apr; 13(4):8323-8333. PubMed ID: 35311628
[TBL] [Abstract][Full Text] [Related]
3. Tripartite motif‑containing 14 may aggravate cardiac hypertrophy via the AKT signalling pathway in neonatal rat cardiomyocytes and transgenic mice.
Hou H; Chen Y; Feng X; Xu G; Yan M
Mol Med Rep; 2023 Sep; 28(3):. PubMed ID: 37503784
[TBL] [Abstract][Full Text] [Related]
4. Aldehyde dehydrogenase 2 deficiency blunts compensatory cardiac hypertrophy through modulating Akt phosphorylation early after transverse aorta constriction in mice.
Xia G; Fan F; Liu M; Wang S; Wu J; Shen C; Han S; Wang C; Jia J; Zou Y; Hu K; Ge J; Sun A
Biochim Biophys Acta; 2016 Sep; 1862(9):1587-93. PubMed ID: 27239698
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA cardiac hypertrophy-associated regulator governs cardiac hypertrophy via regulating miR-20b and the downstream PTEN/AKT pathway.
Zhang M; Jiang Y; Guo X; Zhang B; Wu J; Sun J; Liang H; Shan H; Zhang Y; Liu J; Wang Y; Wang L; Zhang R; Yang B; Xu C
J Cell Mol Med; 2019 Nov; 23(11):7685-7698. PubMed ID: 31465630
[TBL] [Abstract][Full Text] [Related]
6. miR-29a promotes pathological cardiac hypertrophy by targeting the PTEN/AKT/mTOR signalling pathway and suppressing autophagy.
Shi JY; Chen C; Xu X; Lu Q
Acta Physiol (Oxf); 2019 Oct; 227(2):e13323. PubMed ID: 31162869
[TBL] [Abstract][Full Text] [Related]
7. Tripartite motif 32 prevents pathological cardiac hypertrophy.
Chen L; Huang J; Ji Y; Zhang X; Wang P; Deng K; Jiang X; Ma G; Li H
Clin Sci (Lond); 2016 May; 130(10):813-28. PubMed ID: 26884348
[TBL] [Abstract][Full Text] [Related]
8. Toll-interacting protein (Tollip) negatively regulates pressure overload-induced ventricular hypertrophy in mice.
Liu Y; Jiang XL; Liu Y; Jiang DS; Zhang Y; Zhang R; Chen Y; Yang Q; Zhang XD; Fan GC; Li H
Cardiovasc Res; 2014 Jan; 101(1):87-96. PubMed ID: 24285748
[TBL] [Abstract][Full Text] [Related]
9. The RING-domain E3 ubiquitin ligase RNF146 promotes cardiac hypertrophy by suppressing the LKB1/AMPK signaling pathway.
Sheng Z; Xu J; Li F; Yuan Y; Peng X; Chen S; Zhou R; Huang W
Exp Cell Res; 2022 Jan; 410(1):112954. PubMed ID: 34856161
[TBL] [Abstract][Full Text] [Related]
10. Small molecule QF84139 ameliorates cardiac hypertrophy via activating the AMPK signaling pathway.
Li XX; Zhang P; Yang Y; Wang JJ; Zheng YJ; Tan JL; Liu SY; Yan YM; Zhang YY; Cheng YX; Yang HT
Acta Pharmacol Sin; 2022 Mar; 43(3):588-601. PubMed ID: 33967278
[TBL] [Abstract][Full Text] [Related]
11. Lupeol protects against cardiac hypertrophy via TLR4-PI3K-Akt-NF-κB pathways.
Li D; Guo YY; Cen XF; Qiu HL; Chen S; Zeng XF; Zeng Q; Xu M; Tang QZ
Acta Pharmacol Sin; 2022 Aug; 43(8):1989-2002. PubMed ID: 34916609
[TBL] [Abstract][Full Text] [Related]
12. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
13. The oxoglutarate receptor 1 (OXGR1) modulates pressure overload-induced cardiac hypertrophy in mice.
Omede A; Zi M; Prehar S; Maqsood A; Stafford N; Mamas M; Cartwright E; Oceandy D
Biochem Biophys Res Commun; 2016 Oct; 479(4):708-714. PubMed ID: 27693579
[TBL] [Abstract][Full Text] [Related]
14. Cardiac-specific Traf2 overexpression enhances cardiac hypertrophy through activating AKT/GSK3β signaling.
Huang Y; Wu D; Zhang X; Jiang M; Hu C; Lin J; Tang J; Wu L
Gene; 2014 Feb; 536(2):225-31. PubMed ID: 24378234
[TBL] [Abstract][Full Text] [Related]
15. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.
Maejima Y; Usui S; Zhai P; Takamura M; Kaneko S; Zablocki D; Yokota M; Isobe M; Sadoshima J
Circ Heart Fail; 2014 May; 7(3):479-90. PubMed ID: 24526353
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
Miao R; Lu Y; He X; Liu X; Chen Z; Wang J
J Cell Mol Med; 2020 Sep; 24(18):10946-10957. PubMed ID: 32798288
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA302-367-PI3K-PTEN-AKT-mTORC1 pathway promotes the development of cardiac hypertrophy through controlling autophagy.
Jin L; Zhou Y; Han L; Piao J
In Vitro Cell Dev Biol Anim; 2020 Feb; 56(2):112-119. PubMed ID: 31845077
[TBL] [Abstract][Full Text] [Related]
18. C1q-TNF-related protein-3 attenuates pressure overload-induced cardiac hypertrophy by suppressing the p38/CREB pathway and p38-induced ER stress.
Zhang B; Zhang P; Tan Y; Feng P; Zhang Z; Liang H; Duan W; Jin Z; Wang X; Liu J; Gao E; Yu S; Yi D; Sun Y; Yi W
Cell Death Dis; 2019 Jul; 10(7):520. PubMed ID: 31285424
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload.
Chen C; Zou LX; Lin QY; Yan X; Bi HL; Xie X; Wang S; Wang QS; Zhang YL; Li HH
Redox Biol; 2019 Jan; 20():390-401. PubMed ID: 30412827
[TBL] [Abstract][Full Text] [Related]
20. Triad3A attenuates pathological cardiac hypertrophy involving the augmentation of ubiquitination-mediated degradation of TLR4 and TLR9.
Lu X; He Y; Tang C; Wang X; Que L; Zhu G; Liu L; Ha T; Chen Q; Li C; Xu Y; Li J; Li Y
Basic Res Cardiol; 2020 Feb; 115(2):19. PubMed ID: 32008145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
